Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00099
2006-03-15
Retrospective
none
1) Direct Grant for Research (Reference No. 2005.1.082) 2) Neurology Research Funding
Division of Neurology, Department of Medicine& Therapeutics, CUHK
N/A
Dr. Ka Sing Wong
Department of Medicine& Therapeutics
TEL: 2632-3144
jinghaohan@hotmail.com
CUHK
Dr. Ka Sing Wong
Department of Medicine& Therapeutics
TEL: 2632-3471
ks-wong@cuhk.edu.hk
CUHK
Enhanced external counterpulsation(EECP) for atherosclerotic stroke study-A pilot study
Enhanced external counterpulsation(EECP) for atherosclerotic stroke study-A pilot study
EASY-Pilot
CHINA
Yes
2004-04-13
Ischemic Stroke
Device
External Counterpulsation
35 one- hour sessions over a 7 week period
External couterpulsation operates by applying electrocadiogrm-triggerd diastolic pressure of approximately 250 mmHg to the calves, thighs, and buttocks by means of three air-filled cuffs. The effects of EECP are based on the intermittent, sequential inflation of the cuffs at the beginning of diastole and deflation at the end of the diastole. This results in an increase of arterial blood pressure and retrograde aortic blood flow during diastole (diastolic augmentation). At end-diastole, rapid, simultaneous deflation remove all the externally applied pressure to allow forward flow of blood, leaving behind an empty vascular bed in the lower limb to receive the output of the heart, therefore reducing systolic blood pressure(systolic unloading) and cardiac afterload.
Inclusion Criteria: 1)Patient is 18 or above. 2)Clinical evidence of cerebral infarct or transient ischaemic attack in preceding 6 months with relevant large artery occlusive disease at MRA examination. 3)Modified Rankin score (mRS) ≤ 3. 4)Normal platelet count and coagulation profile. 5)Signed informed consent.
Exclusion Criteria: 1)Any medical condition that would not allow the patient to adhere to the protocol or complete the study. 2)Patients with hemorrhagic diathesis, concurrent anti-coagulation treatment, or history of primary intracranial hemorrhage. 3)Other non-ischemic intra-cerebral pathology, e.g. brain tumor, vascular malformation, etc. 4)Clinical evidence of arrhythmias, significant valvular heart disease on echocardiography, or aortic dissection. 5)Thrombophlebitis, ulcers or chronic skin infection of the lower limbs. 6)Clinical evidence of active malignancy. 7)Patients with pre-proliferative, or proliferative diabetic retinopathy.
18
NONE
Both Male and Female
Interventional
Randomized
Active
Single-blind
Crossover
2004-05-03
50
Complete
change in NIHSS and cerebral blood Flow(CVIQ) at end of week 7 and 14
recurrent stroke Percentage of patients with favorable outcome (mRS≤, Barthel Index) at end of week 7 and 14
2009-11-30
ChiCTR-TRC-09000679
2010-05-04
|
|
|
|
---|---|---|---|
No documents yet. |